Clinical trial
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced…
NCT00227617 · University of California, San Francisco, Other · Terminated
Key facts
| NCT number | NCT00227617 |
|---|---|
| Title | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors |
| Official title | A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Genentech, Inc. Industry Sanofi |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin |
| Enrollment | 36 |
| Start date | Jun 8, 2005 |
| Primary completion | Jan 1, 2012 |
| Completion | Feb 1, 2016 |
| First posted | Sep 28, 2005 |
| Last update posted | May 22, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: